Bleeding News and Research

RSS

OrbusNeich's clinical data demonstrates the benefits of Genous Bio-engineered R stent

OrbusNeich announced that clinical data presented today at Asia PCR/Singapore LIVE 2010 demonstrated the benefits of the Genous Bio-engineered R stent in the treatment of two challenging patient subsets.

24 Jan 2010

Final data from Poniard Pharmaceuticals' randomized Phase 2 trial of picoplatin announced

Poniard Pharmaceuticals, Inc., a biopharmaceutical company focused on innovative oncology therapies, today announced final data from a randomized, controlled Phase 2 trial of picoplatin in metastatic colorectal cancer (CRC) patients.

24 Jan 2010

Interventional cardiologist accesses coronary arteries through radial artery on the inside of wrist

In an innovative new procedure, interventional cardiologist Ramesh Mazhari, MD, is one of only a few in the Washington, DC, region to access the coronary arteries through the radial artery on the inside of the wrist.

23 Jan 2010

Ipsen and Inspiration Biopharmaceuticals form strategic partnership

Celtic Pharmaceutical Holdings L.P. ("Celtic Pharma") today announced the formation of a strategic partnership between Ipsen and Inspiration Biopharmaceuticals ("Inspiration") to create a world leading hemophilia franchise, an important milestone for the Celtic Pharma portfolio.

21 Jan 2010

Fourth-quarter and fiscal year 2009 results announced by Somanetics

Somanetics Corporation today reported financial results for the fourth fiscal quarter and year ended November 30, 2009.

21 Jan 2010

FDA approves Thoratec's HeartMate II LVAS for DT

Thoratec Corporation, a world leader in device-based mechanical circulatory support therapies to save, support and restore failing hearts, said today that it has received FDA approval of its PMA (Pre-Market Approval) supplement, allowing the use of its HeartMate II LVAS (Left Ventricular Assist System) for Destination Therapy (DT).

21 Jan 2010

Ipsen enters into partnership agreement with Inspiration Biopharmaceuticals

Ipsen and Inspiration Biopharmaceuticals, Inc. (Inspiration) today announced that they have entered into a partnership to create a world leading hemophilia franchise. The partnership is designed to leverage combined expertise and resources to advance a broad portfolio of recombinant proteins, which address all major hemophilia disorders in a unique way by focusing on two significant unmet needs: wider access to treatment with coagulation factors and treatment for inhibitor complications.

21 Jan 2010

Attaching cartilage to polydioxanone plates facilitates corrective surgery on nasal septum

Attaching cartilage to plates made of the resorbable material polydioxanone appears to facilitate corrective surgery on the nasal septum, the thin cartilage separating the two airways, according to a report in the January/February issue of Archives of Facial Plastic Surgery, one of the JAMA/Archives journals.

19 Jan 2010

AMD LASERS launches Picasso Lite soft tissue dental laser

AMD LASERS today announced the introduction of the Picasso Lite soft tissue dental laser. Priced at $2,495, offering 2.5 Watts of power, and three customizable presets, Picasso Lite is the most affordable and easy-to-operate dental laser in the world.

From AMD Lasers 18 Jan 2010

Early diagnosis can cure endometrial cancer

Postmenopausal women who experience vaginal bleeding should see a doctor promptly. According to the January issue of Mayo Clinic Health Letter, vaginal bleeding is a symptom that occurs early in the course of endometrial cancer, when the chance of a complete cure is the greatest. Even one drop of blood is abnormal in postmenopausal women.

18 Jan 2010

FDA grants orphan drug exclusivity approval for Octapharma AG's wilate

Octapharma AG, one of the largest manufacturers of plasma products in the world, today announced that it has received orphan drug exclusivity approval for wilate® from the U.S. Food and Drug Administration (FDA).

18 Jan 2010

First sulfite-free rectal suspension for UC

sfRowasa™ (mesalamine) Rectal Suspension 4g/60mL –Sulfite-Free Formulation, is the first sulfite-free rectal suspension available for Ulcerative colitis (UC). According to a study published in The American Journal of Gastroenterology, products containing sulfites may exacerbate natural sulfide levels in the colon and may increase inflammation in UC patients. With its sulfite-free preparation, sfRowasa™ offers a new treatment option for the treatment of active, mild to moderate distal ulcerative colitis, proctosigmoiditis or proctitis.

13 Jan 2010

Bevacizumab drug shows promise to slow tumor growth in lung cancer patients

Phase II study results of the agent ASA404 showed promise in patients with either squamous or non-squamous non-small cell lung cancer (NSCLC).

13 Jan 2010

French maritime pine tree extract effective against hemorrhoids

According to the National Digestive Diseases Information Clearinghouse, about half of the U.S. population will have hemorrhoids by the age of 50. While the most common prescription to treat hemorrhoids is over-the-counter remedies, most patients do not report symptoms of acute hemorrhoidal attacks to their doctor until they are in severe distress, including bleeding.

12 Jan 2010

New blood test to identify changes in DNA linked with colorectal cancer now available in the U.S.

A new blood test that identifies changes in DNA associated with colorectal cancer is now available in the U.S. through Quest Diagnostics Incorporated, the world's leading cancer diagnostics company. The test is designed to aid the detection of colorectal cancer, the third leading cause of cancer-related deaths.

12 Jan 2010

Antares Pharma, Population Council report positive Phase 2 results for novel NES/E2 contraceptive gel

Antares Pharma, Inc. and the Population Council today announced successful results from a dose-finding Phase 2 trial for a novel contraceptive gel containing the progestin Nestorone and estradiol (NES/E2) utilizing the Antares ATD (advanced transdermal delivery) gel system. Based on this successful data, the two parties continue to expect to partner with a worldwide or regional pharmaceutical company in order to commercialize this novel contraceptive gel.

12 Jan 2010

Gene therapy may help correct molecular flaws that cause brain disease

Neuroscientists have forged an unlikely molecular union as part of their fight against diseases of the brain and nervous system.

9 Jan 2010

New cardiac procedure may reduce complications and hospital costs

A new approach to common cardiac procedures called transradial angiography might lead to reduced patient complications and recovery time and decreased hospital costs.

7 Jan 2010

ProFibrix B.V. receives loan up to $7.4 million to develop its new hemostat Fibrocaps

ProFibrix B.V., a leader in the development of innovative products for hemostasis and regenerative medicine, today announced that SenterNovem, an agency of the Dutch Ministry of Economic Affairs, has granted the company a loan under its new Innovation Credit scheme of potentially up to EUR 5 million to finance the further clinical development of its unique new hemostat Fibrocaps(TM).

7 Jan 2010

CCAC doubles its efforts to convince Canadians to prevent colorectal cancer

Following the results of the Angus Reid Strategies and the Applied Health Research Centre at Toronto's St. Michael's Hospital survey conducted on behalf of the Canadian Partnership Against Cancer finding that the majority of Canadians have a good understanding of the benefits of colorectal cancer screening, but are not taking action to get screened, the Colorectal Cancer Association of Canada ("CCAC") is doubling its efforts in 2010 to convince Canadians that they must be more proactive concerning their health and the onset of colorectal cancer.

7 Jan 2010